



- (51) **International Patent Classification:**
A61K 31/4245 (2006.01) *A61K 31/24* (2006.01)
- (21) **International Application Number:**
PCT/US2024/031316
- (22) **International Filing Date:**
28 May 2024 (28.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|--------------------------------|----|
| 63/504,306 | 25 May 2023 (25.05.2023) | US |
| 63/578,804 | 25 August 2023 (25.08.2023) | US |
| 63/540,277 | 25 September 2023 (25.09.2023) | US |
| 63/556,028 | 21 February 2024 (21.02.2024) | US |
- (71) **Applicant: MAPLIGHT THERAPEUTICS, INC.**
[US/US]; 800 Chesapeake Drive, Redwood City, California 94063 (US).
- (72) **Inventors: CHEUNG, Culver;** c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **DOUGLAS, Mark;** c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, Cali-

formia 94063 (US). **LILLIE, James;** c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **WOOD, Michael;** c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US).

(74) **Agent: TUSCAN, Michael et al.;** Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV,

(54) **Title:** COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS




FIG. 15

(57) **Abstract:** Combination compositions of Compound 1 and fesoterodine for treating a neurological disorder (such as schizophrenia, Alzheimer's disease psychosis, Parkinson's Disease Psychosis, cognition in Alzheimer's disease, psychosis in dementia with Lewy bodies, bipolar disorders and dyskinesias) are described.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*